v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 45,085 $ 25,314
Short-term investments 10,873 44,381
Research and development tax credits receivable 994 901
Prepaid expenses 2,356 1,840
Other receivables 1,167 1,490
Total current assets 60,475 73,926
Operating lease right-of-use assets 1,234 1,376
Property and equipment 176 197
Total assets 61,885 75,499
Current liabilities    
Accounts payable and accrued liabilities 12,421 7,555
Operating lease liabilities 542 571
Total current liabilities 12,963 8,126
Operating lease liabilities, net of current portion 758 874
Senior secured convertible notes 54,287 53,352
Total liabilities 68,008 62,352
Shareholders' (Deficit) Equity    
Common shares, no par value, unlimited shares authorized 53,464,273 shares issued and outstanding as of March 31, 2025, 53,353,984 shares issued and outstanding as of December 31, 2024 288,188 288,048
Pre-funded warrants - 12,910,590 issued and outstanding as of March 31, 2025 and 12,910,590 as of December 31, 2024 53,076 53,076
Additional paid-in capital 40,919 39,568
Accumulated deficit (388,306) (367,545)
Total shareholders' (deficit) equity (6,123) 13,147
Total liabilities and shareholders' (deficit) equity $ 61,885 $ 75,499